| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Staphylococcal Infections | 7 | 2018 | 1099 | 1.45 | Why? |
| Methicillin-Resistant Staphylococcus aureus | 5 | 2018 | 711 | 1.12 | Why? |
| Bacteremia | 8 | 2019 | 1372 | 1.08 | Why? |
| Republic of Korea | 25 | 2021 | 5858 | 1.00 | Why? |
| Community-Acquired Infections | 4 | 2019 | 2328 | 0.92 | Why? |
| Prescription Drug Overuse | 1 | 2020 | 59 | 0.83 | Why? |
| Klebsiella | 1 | 2019 | 35 | 0.79 | Why? |
| Microbial Sensitivity Tests | 10 | 2019 | 2886 | 0.72 | Why? |
| Methicillin | 1 | 2017 | 73 | 0.70 | Why? |
| Endopeptidases | 1 | 2018 | 228 | 0.69 | Why? |
| Daptomycin | 1 | 2017 | 64 | 0.67 | Why? |
| Gram-Negative Bacterial Infections | 2 | 2019 | 398 | 0.65 | Why? |
| Anti-Bacterial Agents | 12 | 2019 | 10083 | 0.63 | Why? |
| Central Venous Catheters | 1 | 2018 | 188 | 0.63 | Why? |
| Colistin | 1 | 2019 | 217 | 0.63 | Why? |
| beta-Lactamases | 3 | 2019 | 759 | 0.60 | Why? |
| Staphylococcus aureus | 2 | 2018 | 844 | 0.57 | Why? |
| Catheter-Related Infections | 1 | 2018 | 381 | 0.55 | Why? |
| Antimicrobial Stewardship | 1 | 2020 | 931 | 0.47 | Why? |
| Carbapenems | 1 | 2014 | 343 | 0.45 | Why? |
| Escherichia coli | 1 | 2019 | 1547 | 0.44 | Why? |
| Cross Infection | 9 | 2018 | 8675 | 0.44 | Why? |
| Enterobacteriaceae | 1 | 2014 | 395 | 0.42 | Why? |
| Clostridium Infections | 1 | 2018 | 595 | 0.42 | Why? |
| Drug Resistance, Multiple, Bacterial | 1 | 2019 | 1115 | 0.42 | Why? |
| Enterobacteriaceae Infections | 1 | 2014 | 529 | 0.37 | Why? |
| Containment of Biohazards | 1 | 2014 | 762 | 0.36 | Why? |
| Academic Medical Centers | 1 | 2020 | 3088 | 0.35 | Why? |
| Arthroplasty, Replacement, Knee | 1 | 2012 | 363 | 0.33 | Why? |
| Arthroplasty, Replacement, Hip | 1 | 2012 | 403 | 0.33 | Why? |
| Surgical Wound Infection | 1 | 2012 | 501 | 0.33 | Why? |
| Epidemiological Monitoring | 1 | 2018 | 3493 | 0.29 | Why? |
| Vancomycin | 2 | 2018 | 328 | 0.28 | Why? |
| Triazoles | 2 | 2018 | 440 | 0.26 | Why? |
| Gram-Negative Bacteria | 2 | 2019 | 473 | 0.26 | Why? |
| Middle East Respiratory Syndrome Coronavirus | 8 | 2018 | 8843 | 0.25 | Why? |
| Viral Load | 3 | 2020 | 15850 | 0.25 | Why? |
| Blood Culture | 3 | 2019 | 308 | 0.23 | Why? |
| Insurance Claim Review | 1 | 2020 | 108 | 0.21 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 13720 | 0.21 | Why? |
| Drug Monitoring | 2 | 2019 | 1408 | 0.20 | Why? |
| Immunoglobulin Variable Region | 1 | 2021 | 253 | 0.20 | Why? |
| Antibodies, Viral | 7 | 2021 | 51949 | 0.20 | Why? |
| Immunoglobulin Heavy Chains | 1 | 2021 | 222 | 0.20 | Why? |
| Lepidoptera | 1 | 2018 | 26 | 0.19 | Why? |
| Leukocidins | 1 | 2018 | 47 | 0.19 | Why? |
| Programmed Cell Death 1 Receptor | 2 | 2020 | 724 | 0.19 | Why? |
| Glucuronosyltransferase | 1 | 2018 | 24 | 0.19 | Why? |
| Exotoxins | 1 | 2018 | 54 | 0.18 | Why? |
| Hospitals, Teaching | 2 | 2018 | 1609 | 0.18 | Why? |
| Cell Wall | 1 | 2017 | 62 | 0.17 | Why? |
| Herpes Zoster Vaccine | 1 | 2019 | 112 | 0.17 | Why? |
| Bacteria | 2 | 2019 | 1897 | 0.17 | Why? |
| Blood-Borne Pathogens | 1 | 2017 | 54 | 0.17 | Why? |
| Fever of Unknown Origin | 1 | 2018 | 93 | 0.17 | Why? |
| Oligonucleotide Array Sequence Analysis | 1 | 2019 | 343 | 0.17 | Why? |
| Mycobacterium avium Complex | 1 | 2017 | 61 | 0.17 | Why? |
| Local Government | 1 | 2020 | 301 | 0.17 | Why? |
| Bacterial Toxins | 1 | 2018 | 185 | 0.16 | Why? |
| Retrospective Studies | 13 | 2020 | 105322 | 0.16 | Why? |
| Mycobacterium avium-intracellulare Infection | 1 | 2017 | 59 | 0.16 | Why? |
| Calcium Channel Blockers | 1 | 2020 | 367 | 0.16 | Why? |
| Gram-Positive Bacteria | 1 | 2018 | 230 | 0.16 | Why? |
| Influenza, Human | 1 | 2021 | 10779 | 0.16 | Why? |
| beta-Lactams | 1 | 2018 | 210 | 0.16 | Why? |
| Aged | 23 | 2020 | 215776 | 0.15 | Why? |
| T-Lymphocytes, Cytotoxic | 1 | 2020 | 552 | 0.15 | Why? |
| Hospitals, Community | 1 | 2020 | 475 | 0.15 | Why? |
| Prospective Studies | 8 | 2019 | 43301 | 0.15 | Why? |
| Female | 30 | 2020 | 380317 | 0.15 | Why? |
| Population Surveillance | 1 | 2012 | 4967 | 0.15 | Why? |
| Drug Synergism | 1 | 2018 | 833 | 0.14 | Why? |
| Fungi | 1 | 2018 | 471 | 0.14 | Why? |
| Phenotype | 2 | 2017 | 4037 | 0.14 | Why? |
| Imipenem | 1 | 2014 | 57 | 0.14 | Why? |
| Thienamycins | 1 | 2014 | 72 | 0.14 | Why? |
| Male | 29 | 2020 | 367725 | 0.14 | Why? |
| Kinetics | 2 | 2020 | 3238 | 0.14 | Why? |
| Infusions, Intravenous | 1 | 2019 | 1224 | 0.14 | Why? |
| AIDS-Related Opportunistic Infections | 1 | 2017 | 260 | 0.14 | Why? |
| Predictive Value of Tests | 2 | 2020 | 9537 | 0.14 | Why? |
| RNA, Viral | 3 | 2020 | 32276 | 0.13 | Why? |
| Postoperative Complications | 1 | 2012 | 5861 | 0.13 | Why? |
| Lymphocyte Activation | 2 | 2020 | 2742 | 0.13 | Why? |
| Humans | 45 | 2021 | 930598 | 0.13 | Why? |
| beta-Lactam Resistance | 1 | 2014 | 150 | 0.13 | Why? |
| Antibodies, Neutralizing | 5 | 2021 | 25288 | 0.12 | Why? |
| Middle Aged | 23 | 2020 | 270681 | 0.12 | Why? |
| Treatment Failure | 1 | 2018 | 2106 | 0.12 | Why? |
| Aged, 80 and over | 12 | 2020 | 88759 | 0.11 | Why? |
| Area Under Curve | 1 | 2019 | 2564 | 0.11 | Why? |
| Antiretroviral Therapy, Highly Active | 1 | 2017 | 952 | 0.11 | Why? |
| Polymorphism, Genetic | 1 | 2018 | 1074 | 0.11 | Why? |
| Antifungal Agents | 2 | 2018 | 1828 | 0.11 | Why? |
| Adult | 20 | 2020 | 244371 | 0.10 | Why? |
| Risk Factors | 7 | 2019 | 71621 | 0.10 | Why? |
| Infection Control | 2 | 2020 | 23131 | 0.10 | Why? |
| Plasma | 1 | 2020 | 1809 | 0.10 | Why? |
| Sputum | 1 | 2018 | 1720 | 0.10 | Why? |
| Klebsiella Infections | 1 | 2014 | 466 | 0.10 | Why? |
| Frail Elderly | 1 | 2019 | 1427 | 0.10 | Why? |
| Drug Prescriptions | 1 | 2018 | 1062 | 0.10 | Why? |
| Antibody Formation | 2 | 2020 | 4038 | 0.10 | Why? |
| Hepatitis B | 1 | 2017 | 888 | 0.10 | Why? |
| Multivariate Analysis | 3 | 2018 | 5440 | 0.09 | Why? |
| Enzyme-Linked Immunosorbent Assay | 4 | 2021 | 7868 | 0.09 | Why? |
| Klebsiella pneumoniae | 1 | 2014 | 658 | 0.09 | Why? |
| Seasons | 1 | 2021 | 4071 | 0.09 | Why? |
| Delayed Diagnosis | 1 | 2018 | 1529 | 0.09 | Why? |
| Survivors | 1 | 2020 | 2619 | 0.09 | Why? |
| Intensive Care Units | 3 | 2020 | 29594 | 0.09 | Why? |
| Antihypertensive Agents | 1 | 2020 | 1962 | 0.09 | Why? |
| Mice, Inbred BALB C | 1 | 2018 | 5814 | 0.09 | Why? |
| Coronavirus Infections | 14 | 2020 | 253789 | 0.08 | Why? |
| Immunity, Cellular | 1 | 2020 | 3614 | 0.08 | Why? |
| Bacterial Infections | 1 | 2020 | 2229 | 0.08 | Why? |
| ROC Curve | 1 | 2019 | 6024 | 0.08 | Why? |
| CD8-Positive T-Lymphocytes | 2 | 2020 | 5837 | 0.08 | Why? |
| Proportional Hazards Models | 1 | 2019 | 6543 | 0.08 | Why? |
| Hepatitis C | 1 | 2017 | 1514 | 0.08 | Why? |
| Young Adult | 9 | 2020 | 93724 | 0.07 | Why? |
| Bacterial Proteins | 1 | 2014 | 1318 | 0.07 | Why? |
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2019 | 449 | 0.07 | Why? |
| Respiratory System | 1 | 2018 | 3213 | 0.07 | Why? |
| Disease Outbreaks | 5 | 2021 | 27595 | 0.07 | Why? |
| Neutralization Tests | 2 | 2017 | 6698 | 0.07 | Why? |
| Antibiotic Prophylaxis | 2 | 2018 | 399 | 0.07 | Why? |
| Personnel, Hospital | 1 | 2017 | 2273 | 0.07 | Why? |
| Ultrasonography | 1 | 2020 | 4409 | 0.07 | Why? |
| Logistic Models | 1 | 2019 | 9089 | 0.07 | Why? |
| Reproducibility of Results | 1 | 2020 | 11304 | 0.07 | Why? |
| Angiotensin Receptor Antagonists | 1 | 2020 | 3892 | 0.07 | Why? |
| Tertiary Care Centers | 2 | 2019 | 8248 | 0.06 | Why? |
| Health Care Surveys | 1 | 2012 | 2942 | 0.06 | Why? |
| Tuberculosis | 1 | 2018 | 2895 | 0.06 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 5277 | 0.06 | Why? |
| Cohort Studies | 3 | 2020 | 36005 | 0.06 | Why? |
| Incidence | 4 | 2018 | 25622 | 0.06 | Why? |
| HIV Infections | 2 | 2017 | 11620 | 0.06 | Why? |
| Virus Shedding | 1 | 2018 | 5834 | 0.06 | Why? |
| Body Temperature | 2 | 2017 | 875 | 0.05 | Why? |
| Cytokines | 3 | 2020 | 15010 | 0.05 | Why? |
| Infant | 2 | 2020 | 30274 | 0.05 | Why? |
| Administration, Oral | 2 | 2018 | 2340 | 0.05 | Why? |
| Acute-Phase Reaction | 1 | 2020 | 116 | 0.05 | Why? |
| Clone Cells | 1 | 2021 | 312 | 0.05 | Why? |
| Ki-67 Antigen | 1 | 2020 | 139 | 0.05 | Why? |
| Granzymes | 1 | 2020 | 197 | 0.05 | Why? |
| Perforin | 1 | 2020 | 136 | 0.05 | Why? |
| Prevalence | 3 | 2018 | 25773 | 0.05 | Why? |
| Prodromal Symptoms | 1 | 2020 | 133 | 0.05 | Why? |
| Immunoglobulin G | 2 | 2021 | 21571 | 0.05 | Why? |
| Time Factors | 5 | 2020 | 31397 | 0.05 | Why? |
| Practice Patterns, Physicians' | 1 | 2018 | 4927 | 0.05 | Why? |
| Nanospheres | 1 | 2019 | 34 | 0.05 | Why? |
| Korea | 1 | 2018 | 89 | 0.05 | Why? |
| Pandemics | 7 | 2020 | 389249 | 0.05 | Why? |
| Occupational Exposure | 1 | 2017 | 4742 | 0.05 | Why? |
| Length of Stay | 2 | 2017 | 11042 | 0.05 | Why? |
| Mice | 1 | 2018 | 21357 | 0.05 | Why? |
| Interferon-gamma | 2 | 2020 | 2711 | 0.05 | Why? |
| Enzyme-Linked Immunospot Assay | 1 | 2019 | 325 | 0.04 | Why? |
| Suspensions | 1 | 2018 | 63 | 0.04 | Why? |
| Vancomycin Resistance | 1 | 2018 | 55 | 0.04 | Why? |
| Multilocus Sequence Typing | 1 | 2018 | 264 | 0.04 | Why? |
| Drug Resistance, Multiple | 1 | 2018 | 156 | 0.04 | Why? |
| Biomarkers | 1 | 2020 | 23361 | 0.04 | Why? |
| Adolescent | 6 | 2019 | 86841 | 0.04 | Why? |
| Self Report | 2 | 2020 | 3802 | 0.04 | Why? |
| Critical Care | 1 | 2020 | 14081 | 0.04 | Why? |
| Virus Replication | 1 | 2018 | 14331 | 0.04 | Why? |
| Critical Illness | 1 | 2020 | 17281 | 0.04 | Why? |
| Camelus | 2 | 2015 | 1425 | 0.04 | Why? |
| Histocompatibility Antigens Class I | 1 | 2020 | 624 | 0.04 | Why? |
| Virulence Factors | 1 | 2018 | 338 | 0.04 | Why? |
| Immunophenotyping | 1 | 2020 | 1290 | 0.04 | Why? |
| Pharyngitis | 1 | 2020 | 687 | 0.04 | Why? |
| Animals | 4 | 2018 | 78931 | 0.04 | Why? |
| Public Health | 1 | 2021 | 16359 | 0.04 | Why? |
| Pneumonia, Viral | 5 | 2020 | 243684 | 0.04 | Why? |
| Reverse Transcription | 1 | 2018 | 673 | 0.04 | Why? |
| Prothrombin Time | 1 | 2016 | 434 | 0.03 | Why? |
| Real-Time Polymerase Chain Reaction | 3 | 2020 | 11367 | 0.03 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2017 | 9706 | 0.03 | Why? |
| Interrupted Time Series Analysis | 1 | 2018 | 868 | 0.03 | Why? |
| Drug Resistance, Microbial | 1 | 2018 | 419 | 0.03 | Why? |
| Endemic Diseases | 1 | 2018 | 480 | 0.03 | Why? |
| Lung | 2 | 2020 | 31049 | 0.03 | Why? |
| Microscopy, Electron | 1 | 2016 | 830 | 0.03 | Why? |
| Hyperbaric Oxygenation | 1 | 2016 | 268 | 0.03 | Why? |
| Spike Glycoprotein, Coronavirus | 2 | 2021 | 37182 | 0.03 | Why? |
| Molecular Epidemiology | 1 | 2018 | 1638 | 0.03 | Why? |
| Independent Living | 1 | 2019 | 842 | 0.03 | Why? |
| Chemokine CXCL10 | 1 | 2016 | 565 | 0.03 | Why? |
| Data Accuracy | 1 | 2018 | 715 | 0.03 | Why? |
| Alleles | 1 | 2018 | 1557 | 0.03 | Why? |
| CD4 Lymphocyte Count | 1 | 2017 | 1517 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2018 | 2324 | 0.03 | Why? |
| Antibody Affinity | 1 | 2015 | 1078 | 0.03 | Why? |
| Sex Distribution | 1 | 2018 | 2083 | 0.03 | Why? |
| Leukocytes, Mononuclear | 1 | 2020 | 2115 | 0.03 | Why? |
| Betacoronavirus | 5 | 2020 | 204454 | 0.03 | Why? |
| Recombinant Proteins | 1 | 2021 | 3786 | 0.03 | Why? |
| Chemokines | 1 | 2016 | 1095 | 0.03 | Why? |
| Taiwan | 1 | 2018 | 2556 | 0.03 | Why? |
| Creatinine | 1 | 2016 | 1443 | 0.03 | Why? |
| Health Personnel | 1 | 2020 | 29646 | 0.03 | Why? |
| History, 21st Century | 1 | 2017 | 1849 | 0.02 | Why? |
| Convalescence | 1 | 2020 | 2829 | 0.02 | Why? |
| Epitopes, T-Lymphocyte | 1 | 2020 | 2262 | 0.02 | Why? |
| Drug Resistance, Bacterial | 1 | 2019 | 1414 | 0.02 | Why? |
| Immunologic Memory | 1 | 2020 | 3362 | 0.02 | Why? |
| Lymphocyte Count | 1 | 2020 | 4758 | 0.02 | Why? |
| Age Distribution | 1 | 2018 | 3567 | 0.02 | Why? |
| Tuberculosis, Pulmonary | 1 | 2018 | 1171 | 0.02 | Why? |
| Diarrhea | 1 | 2020 | 2743 | 0.02 | Why? |
| Lymphopenia | 1 | 2020 | 2669 | 0.02 | Why? |
| Protein Domains | 1 | 2021 | 6563 | 0.02 | Why? |
| Asymptomatic Diseases | 1 | 2020 | 3444 | 0.02 | Why? |
| Workload | 1 | 2017 | 1887 | 0.02 | Why? |
| Leukocyte Count | 1 | 2016 | 3178 | 0.02 | Why? |
| Hospitalization | 1 | 2018 | 54280 | 0.02 | Why? |
| Sequence Analysis, RNA | 1 | 2016 | 2290 | 0.02 | Why? |
| Oxygen Inhalation Therapy | 1 | 2020 | 3629 | 0.02 | Why? |
| Social Support | 1 | 2020 | 3183 | 0.02 | Why? |
| Cough | 1 | 2020 | 4891 | 0.02 | Why? |
| Serologic Tests | 1 | 2020 | 4359 | 0.02 | Why? |
| Odds Ratio | 1 | 2017 | 5861 | 0.02 | Why? |
| Japan | 1 | 2018 | 6653 | 0.02 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2020 | 4545 | 0.02 | Why? |
| Public Health Surveillance | 1 | 2018 | 3129 | 0.02 | Why? |
| Hospitals, University | 1 | 2017 | 4173 | 0.02 | Why? |
| Severity of Illness Index | 3 | 2018 | 48226 | 0.02 | Why? |
| Renin-Angiotensin System | 1 | 2020 | 3661 | 0.02 | Why? |
| Patient Discharge | 1 | 2020 | 5696 | 0.02 | Why? |
| Hematologic Neoplasms | 1 | 2018 | 2105 | 0.02 | Why? |
| Stress Disorders, Post-Traumatic | 1 | 2020 | 2963 | 0.02 | Why? |
| Protein Binding | 1 | 2021 | 11430 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2018 | 7220 | 0.02 | Why? |
| C-Reactive Protein | 1 | 2020 | 7972 | 0.02 | Why? |
| Dyspnea | 1 | 2016 | 3847 | 0.02 | Why? |
| Radiography, Thoracic | 1 | 2020 | 5486 | 0.02 | Why? |
| Fever | 1 | 2020 | 7795 | 0.02 | Why? |
| Clinical Competence | 1 | 2017 | 3263 | 0.01 | Why? |
| Surveys and Questionnaires | 2 | 2020 | 43792 | 0.01 | Why? |
| Seroepidemiologic Studies | 1 | 2017 | 10017 | 0.01 | Why? |
| Asymptomatic Infections | 1 | 2020 | 7218 | 0.01 | Why? |
| Sex Factors | 1 | 2018 | 11014 | 0.01 | Why? |
| Polymerase Chain Reaction | 1 | 2016 | 6740 | 0.01 | Why? |
| Mutation | 1 | 2021 | 12376 | 0.01 | Why? |
| Neutrophils | 1 | 2016 | 5476 | 0.01 | Why? |
| Vero Cells | 1 | 2016 | 14117 | 0.01 | Why? |
| Case-Control Studies | 1 | 2018 | 17671 | 0.01 | Why? |
| Peptidyl-Dipeptidase A | 1 | 2020 | 9659 | 0.01 | Why? |
| Hypertension | 1 | 2020 | 8895 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2017 | 17020 | 0.01 | Why? |
| Interleukin-6 | 1 | 2016 | 7522 | 0.01 | Why? |
| Health Policy | 1 | 2018 | 6242 | 0.01 | Why? |
| Hospitals | 1 | 2018 | 11793 | 0.01 | Why? |
| Disease Progression | 1 | 2016 | 13580 | 0.01 | Why? |
| Phylogeny | 1 | 2016 | 13341 | 0.01 | Why? |
| Depression | 1 | 2020 | 14116 | 0.01 | Why? |
| Comorbidity | 1 | 2020 | 34796 | 0.01 | Why? |
| Prognosis | 1 | 2018 | 32490 | 0.01 | Why? |
| Tomography, X-Ray Computed | 1 | 2020 | 25144 | 0.01 | Why? |
| Child | 1 | 2020 | 70012 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2018 | 53120 | 0.01 | Why? |
| Antiviral Agents | 1 | 2018 | 41703 | 0.00 | Why? |